Ballard Spahr advised Pyramid Biosciences on the deal. Clinical-stage biotechnology company Pyramid Biosciences, Inc. announced the development of a global licensing deal for two cancer therapies worth...
This content is for Standard 1 Year members only. LoginJoin Now